Innovation: Therapeutic Areas
In addition to therapeutic vaccines for solid tumors, Orbis scientists are developing a diagnostic/cancer vaccine for blood borne cancers which would require a device to "debulk" a patient's blood to remove tumor tissue.
Born out of our fascination with the human immune system (our body’s best medicine), 7Twelve Labs is a subsidiary of Orbis that has developed a pipeline of transformative products for the skin and mouth that enhance the body’s immune system and its natural ability to repair and restore health.
Orbis' proprietary Yeast Cell Wall Particle (YCWP) Delivery Technology has demonstrated a high level of effectiveness as seen with our novel particle-based vaccines. COVID-19 and any other future viral challenges will require new vaccine strategies in order to more quickly respond to any national or global epidemic.
Based on our proven vaccine technology Orbis is developing a cancer vaccine for companion animals. Our first target indication is osteosarcoma in dogs – a devastating cancer for large breed dogs for which there are currently limited treatments after the amputation of a limb.
Cancer continues to be one of the world’s most intractable problems. And we see this as an exciting and worthwhile challenge. Through our subsidiary, Elios Therapeutics, Orbis is developing the Tumor Lysate, Particle Only (TLPO) vaccine, an autologous or personalized therapeutic cancer vaccine designed to stimulate the immune system to recognize tumor cells and fight a patient’s specific cancer.
Orbis is committed to eradicating cancer and immune-mediated conditions through the development of transformative medicines that target the body’s immune system and ignite its natural ability to repair and restore health.
We do this through internal research and development, as well as through collaborations with academic and industry partners.
